H’ers took over 150 projects to the Colorado State Fair this year in the general and Family and Consumer Science categories. They brought home numerous awards, including 24 ...

GE’s Opal ice maker is considered one of the best-in-class appliances for making the revered crunchy-chewy “nugget” ice that’s a hallmark of fast-food chains like Sonic. With a detachable 1-gallon ...

California built a $2.2 billion solar thermal project in the Mojave Desert in the early 2010s, with 75% of it funded by the Obama administration through loan guarantees. In January, Pacific Gas & ...

Prime Day is the perfect time to stock up on big-ticket items that would otherwise be too expensive to purchase — and this October, the deals are too good to miss. Whether you want to add a touch of ...

WILMINGTON — Shoppers, supporters, and survivors are invited to celebrate the grand reopening of Great Stuff Savvy Resale & Home this Friday, Oct. 10, from 10 a.m. to 4 p.m. at the Talleyville ...

UC Berkeley emeritus professor John Clarke, UC Santa Barbara professor Michel H. Devoret and UC Santa Barbara professor John M. Martinis were awarded the 2025 Nobel Prize in physics for their ...

Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.

The Statesboro City Council approved its five-year Strategic Plan on October 7, alongside multiple infrastructure actions and updates from City Manager Charles Penny on upcoming referenda, code ...

On October 6, Portuguese quantum computing firm Quantica Tech announced the development of Quantic Bitcoin (BTCQ). It is a quantum interoperability protocol to connect traditional blockchain networks ...

Architecture goes beyond its fundamental function of defining spaces and providing protection; it shapes the user experience, influencing sensations of comfort, spaciousness, and well-being. Among the ...

Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.